Core Viewpoint - The city of Dingxi is leveraging its rich heritage in traditional Chinese medicine (TCM) to transform into a major hub for the TCM industry, aiming for a total industry scale of 50.7 billion yuan by 2024 [1] Group 1: Achievements in Standardized Planting System - Dingxi has made significant progress in establishing a standardized planting system, creating the largest medicinal plant genetic resource bank in Northwest China, preserving 6,488 samples of 324 types of medicinal seeds [2] - The city has built the only medicinal seed processing factory in Gansu Province, processing over 1,000 tons of medicinal seeds annually [2] - The standardized planting rate for medicinal herbs in Dingxi has reached 84.2%, with 420,000 acres designated as GAP demonstration bases [2] Group 2: Achievements in Deep Processing System - Dingxi has capitalized on opportunities for processing local medicinal herbs, establishing over 60 processing workshops with 33 TCM processing enterprises, processing 370,000 tons of medicinal materials annually [3] - The city has developed five TCM industrial parks and attracted 16 top national TCM enterprises, with 115 TCM processing companies operating in Dingxi [3] - The annual processing output value of TCM products has reached 10.2 billion yuan, covering various product lines including TCM decoction pieces and biomedicine [3] Group 3: Achievements in Specialized Market System - Dingxi's climate is conducive to TCM storage, leading to an expansion in storage capacity and modernization of trading markets, achieving a static storage capacity of 1.4 million tons [3] - The city has established a market system with five major markets, achieving an annual trading volume of over 1.5 million tons and a transaction value close to 30 billion yuan [3] Group 4: Achievements in Integrated Development System - Dingxi is seizing the opportunity to build a national TCM innovation development pilot zone, promoting the integration of medical care and health services [4] - The establishment of a regional medical center has led to a comprehensive TCM treatment system across hospitals, with all hospitals setting up TCM departments [4] - The city has developed over 110 types of TCM health products and established various health and wellness centers, enhancing the capacity for TCM health services [4]

Company Overview - Tian Da Pharmaceutical focuses on the development of traditional Chinese medicine, innovative drugs, and healthcare services, aiming to become a competitive player in the pharmaceutical industry [4] - The company is building a comprehensive traditional Chinese medicine industry chain, establishing quality control standards, and creating a new type of traditional Chinese medicine clinic [4] - Tian Da Pharmaceutical utilizes advanced technologies such as big data and artificial intelligence to enhance its healthcare services and expand its market reach [4] Financial Performance - As of December 31, 2024, Tian Da Pharmaceutical reported total revenue of 306 million yuan, a year-on-year decrease of 37.99% [2] - The company recorded a net loss attributable to shareholders of 56.83 million yuan, a significant decline of 154.07% compared to the previous year [2] - The gross profit margin stood at 46.08%, with a debt-to-asset ratio of 33.9% [2] Market Position and Valuation - Tian Da Pharmaceutical's price-to-earnings (P/E) ratio is -4.73, ranking 138th in the industry, while the average P/E ratio for the pharmaceutical and biotechnology sector is 2.79 [3] - The company has underperformed the Hang Seng Index, with a cumulative decline of 20.12% this year, compared to the index's increase of 19.78% [2] Industry Context - The pharmaceutical and biotechnology industry has an average P/E ratio of 2.79, with a median of 6.7 [3] - Competitors in the industry include other pharmaceutical companies with varying P/E ratios, such as Jingxin Pharmaceutical at 0.86 and Dongrui Pharmaceutical at 3.03 [3]

Company Overview - Tian Da Pharmaceutical Co., Ltd. focuses on the development of traditional Chinese medicine, innovative drugs, and healthcare services, aiming to become a competitive player in the pharmaceutical and healthcare sectors [4] - The company is building a comprehensive traditional Chinese medicine industry chain, establishing quality control standards for Chinese medicinal materials, and creating a new type of Chinese medicine clinic called "Tian Da Clinic" [4] - Tian Da Pharmaceutical utilizes internet technology, big data, and artificial intelligence to integrate online and offline services, providing comprehensive healthcare services [4] Financial Performance - As of December 31, 2024, Tian Da Pharmaceutical reported total revenue of 306 million yuan, a year-on-year decrease of 37.99% [2] - The company recorded a net loss attributable to shareholders of 56.83 million yuan, a significant decline of 154.07% year-on-year [2] - The gross profit margin stood at 46.08%, with a debt-to-asset ratio of 33.9% [2] Market Position and Valuation - Currently, there are no institutional investment ratings for Tian Da Pharmaceutical [3] - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 5.44 times, with a median of 4.53 times [3] - Tian Da Pharmaceutical has a P/E ratio of -5.26 times, ranking 125th in the industry [3] - Comparatively, other companies in the sector have P/E ratios ranging from 0.72 times to 4.28 times [3] Recent Stock Performance - As of May 9, the Hang Seng Index increased by 0.4%, closing at 22,867.74 points [1] - Tian Da Pharmaceutical's stock price was 0.162 HKD per share, reflecting an increase of 8.0% with a trading volume of 2,000 shares and a turnover of 326 HKD [1] - Over the past month, the stock has experienced a cumulative decline of 10.71%, and a year-to-date decline of 11.24%, underperforming the Hang Seng Index's increase of 13.54% [2]